Results 41 to 50 of about 170,525 (342)

The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease

Frontiers in Physiology, 2012
Alcoholic liver disease (ALD) encompasses hepatic steatosis, which may progress to alcoholic hepatitis, fibrosis, and cirrhosis. It remains a leading cause of morbidity and mortality in the US and worldwide.
Phillipp eHartmann, Wei-Chung eChen, Bernd eSchnabl   +2 more
doaj   +1 more source

Two-hour postload glycemia is associated to an increased risk of NAFLD in healthy subjects with family history of type 2 diabetes: a case control study [PDF]

, 2016
Nonalcoholic fatty liver disease (NAFLD) includes steatosis and nonalcoholic steatohepatitis (NASH), which can be complicated by cirrhosis and hepatocellular carcinoma [1].
CARNOVALE, ANNA, FILARDI, TIZIANA, LENZI, Andrea, MARIANI, Paola, MORANO, Susanna, Nieddu, Luciano, PALLOTTA, Nadia, VINCOLI, GIUSEPPINA   +7 more
core   +1 more source

New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease

Cells, 2019
Non-alcoholic steatohepatitis (NASH) is a major cause of chronic liver disease. However, most available animal models fail to reflect the whole spectrum of the disease.
Raquel Maeso-Díaz, Zoe Boyer-Diaz, Juan José Lozano, Martí Ortega-Ribera, Carmen Peralta, Jaime Bosch, Jordi Gracia-Sancho   +6 more
doaj   +1 more source

Deficiency of the purinergic receptor 2X7 attenuates nonalcoholic steatohepatitis induced by high-fat diet. possible role of the NLRP3 Inflammasome [PDF]

, 2017
Molecular mechanisms driving transition from simple steatosis to nonalcoholic steatohepatitis (NASH), a critical step in the progression of nonalcoholic fatty liver disease (NAFLD) to cirrhosis, are poorly defined. This study aimed at investigating the
Blasetti Fantauzzi, Claudia, Iacobini, Carla, Menini, Stefano, Pugliese, Giuseppe, Rossi, Chiara, Santini, Eleonora, Solini, Anna   +6 more
core   +3 more sources

Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis. [PDF]

, 2015
Palmitic acid (PA) induces hepatocyte apoptosis and fuels de novo ceramide synthesis in the endoplasmic reticulum (ER). Myristic acid (MA), a free fatty acid highly abundant in copra/palmist oils, is a predictor of nonalcoholic steatohepatitis (NASH) and
Alarcón-Vila, C, Baulies, A, Caballeria, J, Casas, J, Elena, M, Fabriàs, G, Fernandez-Checa, JC, García-Ruiz, C, Martinez Gili, L, Torres, S   +9 more
core   +2 more sources

Infections increase the risk of decompensation and death in patients with early alcohol-related liver disease

JHEP Reports
Background & Aims: Infections are frequent in patients with cirrhosis and worsen prognosis. We evaluated the incidence of infections and their impact on decompensation and death in patients with early alcohol-related liver disease (ALD) during long ...
Stine Johansen, Simon Langkjær, Ditlev Nytoft Rasmussen, Mads Israelsen, Nikolaj Torp, Katrine Lindvig, Maria Kjærgaard, Johanne Kragh Hansen, Camilla Dalby Hansen, Katrine Thorhauge, Peter Andersen, Sönke Detlefsen, Helene Bæk Juel, Ulrik Stenz Justesen, Torben Hansen, Aleksander Krag, Maja Thiele, Ema Anastasiadou, Manimozhian Arumugam, Peer Bork, Torben Hansen, Jenny Presto, Hans Israelsen, Morten Karsdal, Cristina Legido-Quigley, Hans Olav Melberg, Maja Thiele, Jonel Trebicka, Aleksander Krag, Peer Bork, Mathias Mann, Jelle Matthijnssens, Aleksander Krag, Torben Hansen   +33 more
doaj   +1 more source

Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity [PDF]

, 2016
Objective: This study aimed to evaluate whether circulating levels and/or visceral adipose tissue (VAT) expression of recently described adipokines associate with histopathological severity of nonalcoholic fatty liver disease (NAFLD), independent of ...
Alfadda, Behari, Bekaert, Bozaoglu, Brunt, Bugianesi, Chakaroun, Deng, Docke, Donnelly, Ehrlund, Fuster, Greulich, Gruben, Haukeland, Heiker, Kanda, Kim, Kleiner, Luangsay, Mahdi, Marchesini, Musso, Ouwens, Polyzos, Polyzos, Rivera, Saxena, Seki, Sell, Sell, Souza Batista, Wittamer, Wittamer, Wolfs, Wong, Yang, Yilmaz, Zelber-Sagi, Zeng   +39 more
core   +1 more source

Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH

Hepatology Communications, 2021
The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and NAFLD‐related cirrhosis in the United States and globally highlights the need to better understand the mechanisms causing progression of hepatic steatosis to fibrosing steatohepatitis ...
C. Horn, Amilcar L. Morales, Christopher Savard, G. Farrell, G. Ioannou   +4 more
semanticscholar   +1 more source

Non-invasive tests for MetALD and alcohol-related liver diseaseKeypoints

JHEP Reports
Summary: Metabolic- and alcohol-related liver disease (MetALD) and alcohol-related liver disease (ALD) are major drivers of the global burden of cirrhosis. While metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly one-third of
Stine Johansen, Maja Thiele, Aleksander Krag   +2 more
doaj   +1 more source

Immune and Inflammatory Pathways in Non-Alcoholic Steatohepatitis (NASH). An update [PDF]

, 2019
Non-alcoholic steatohepatitis (NASH), also known as fatty liver disease (FLD), is a major public health problem. It is considered to be the hepatic manifestation of the metabolic syndrome.
Breaban, Iulia, Coste, Sorina Cezara, Cozma, Angela, Negrean, Vasile, Orasan, Olga Hilda, Popovici, Ionela, Procopciuc, Lucia Maria, Sampelean, Dorel, Sitar Taut, Adela, Stefan, Andreea Maria, Tarmure Sarlea, Simina   +10 more
core   +1 more source